The luminal A subtype has the best clinical prognosis, accounting for 40% of all subtypes, and is characterized by high levels of ER expression; therefore, patients with luminal A BC are more likely to benefit from hormone therapy alone. This evidence concerns the gene ESR1 and breast cancer.